Life Sciences VCs Deserve a Chance with a New LP Base
It isn't private equity firms that ought to be reaping bigger balance sheets from some of the smallest investors. If life sciences & biotech venture capitalists are to make it through industry-wide consolidation, they should have access to a new class of capital. How about 401(k)s?
17 October 2012•3 mins read
